A Phase 3 trial of a drug being developed by AstraZeneca Plc for patients with a specific mutation in lung cancer has failed to meet its primary endpoint of progression free survival, the company announced on 9 August. The drug, selumetinib, is a MEK 1/2 inhibitor.
